Discover
Visualize rapid, validated insights through real-world data.
Aetion has entered into an agreement to be acquired by Datavant, a leading health data platform company. Learn more →
Aetion offers generous benefits to its full-time employees, which currently can include:
The benefits offering may differ based on geographies where employees are based, when outside of the United States.
These datasets provide broad-scale insights into treatment patterns, safety monitoring, and real-world effectiveness. Regulators and payers rely on these sources for post-market safety studies, reimbursement decisions, and health economics evaluations.
Aetion works with leading data providers such as Optum, HealthVerity, IBM MarketScan, and BHI to ensure high-quality, structured claims and EHR data for regulatory applications.
As regulatory bodies shift toward biomarker-driven approvals and personalized treatment strategies, genomic and precision medicine data is critical for rare disease research, label expansions, and advanced clinical trial designs.
Our partnerships with Guardant Health, Tempus, Invitae, and Flatiron enable us to generate fit-for-purpose, regulatory-aligned real-world evidence (RWE) in oncology, rare diseases, and targeted therapies.
Aetion partners with leading providers of disease-contextualized data to deliver insights for RWE generation.
For oncology, hematology, and rare diseases, datasets from ConcertAI, COTA, and Treat-NMD allow us to deliver disease-specific insights for regulatory filings, HEOR, and payer engagement.
Connect with us to work with the team advancing critical decisions in healthcare.